More on ONC
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $260.27 |
|
|||
| Open | $261.64 | ||||
| 52 Wk High | $0.35 | ||||
| 52 Wk Low | $0.35 | ||||
| Day High | $267.56 | ||||
| Day Low | $261.50 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 260,964 | ||||
- BeOne Medicines’ Foundational Hematology Franchise Leads Next Era of B-Cell Cancer Innovation at EHA 2026
- BeOne presents phase 3 data showing BRUKINSA benefits in elderly CLL patients
- BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
- Form 4 BeOne Medicines Ltd. For: Jun 08 Filed by: Ball Titus B.
- Form 4 BeOne Medicines Ltd. For: Jun 08 Filed by: Lee Chan Henry
- Form 4 BeOne Medicines Ltd. For: Jun 08 Filed by: Wang Lai
- Form 4 BeOne Medicines Ltd. For: Jun 08 Filed by: Wu Xiaobin
- Form 4 BeOne Medicines Ltd. For: Jun 08 Filed by: OYLER JOHN
- Form 4 BeOne Medicines Ltd. For: Jun 01 Filed by: Yi Qingqing
- BeOne Medicines (ONC) Reiterated at Market Outperform by Citizens
Entities mentioned with ONC
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Definitive Agreement | View Related Stories »
- Canaccord Genuity | View Related Stories »
- RBC Capital | View Related Stories »
- Show More...
